Amicus appoints Bradley Campbell CBO
This article was originally published in Scrip
Executive Summary
Amicus Therapeutics, a developer of therapies for rare and orphan diseases, has promoted Bradley Campbell to chief business officer. Mr Campbell joined Amicus in 2006 and most recently served as senior vice-president of business operations. He will continue to report to John Crowley, Amicus' chair and CEO.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.